Eli Lilly and (NYSE:LLY – Get Rating) was downgraded by StockNews.com from a “strong-buy” rating to a “buy” rating in a report issued on Thursday.
A number of other research firms have also recently weighed in on LLY. The Goldman Sachs Group started coverage on shares of Eli Lilly and in a report on Friday, December 17th. They issued a “neutral” rating and a $236.00 price objective for the company. BMO Capital Markets boosted their price target on shares of Eli Lilly and from $311.00 to $320.00 and gave the stock an “outperform” rating in a research report on Thursday, December 16th. Barclays boosted their price target on shares of Eli Lilly and from $280.00 to $325.00 and gave the stock an “overweight” rating in a research report on Monday, December 20th. Mizuho lowered their price target on shares of Eli Lilly and from $302.00 to $293.00 and set a “buy” rating on the stock in a research report on Friday, February 4th. Finally, JPMorgan Chase & Co. restated a “buy” rating on shares of Eli Lilly and in a research report on Thursday, December 16th. One equities research analyst has rated the stock with a sell rating, three have given a hold rating and fifteen have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $289.50.
LLY opened at $276.44 on Thursday. Eli Lilly and has a fifty-two week low of $178.58 and a fifty-two week high of $283.90. The company has a debt-to-equity ratio of 1.68, a quick ratio of 0.97 and a current ratio of 1.23. The company has a fifty day moving average of $249.21 and a two-hundred day moving average of $250.24. The stock has a market capitalization of $263.27 billion, a price-to-earnings ratio of 45.02, a PEG ratio of 2.21 and a beta of 0.41.
Follow Eli Lilly’s (NYSE:LLY) Lead, and Make a Big Purchase
Eli Lilly and (NYSE:LLY – Get Rating) last released its quarterly earnings data on Thursday, February 3rd. The company reported $2.49 earnings per share for the quarter, missing analysts’ consensus estimates of $2.51 by ($0.02). Eli Lilly and had a net margin of 19.71% and a return on equity of 96.36%. The firm had revenue of $8 billion during the quarter, compared to analysts’ expectations of $7.89 billion. During the same period in the previous year, the firm posted $2.75 EPS. The firm’s quarterly revenue was up 7.5% on a year-over-year basis. On average, equities research analysts forecast that Eli Lilly and will post 8.64 earnings per share for the current year.
In related news, major shareholder Lilly Endowment Inc sold 3,570 shares of the company’s stock in a transaction that occurred on Monday, December 27th. The shares were sold at an average price of $279.53, for a total transaction of $997,922.10. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CAO Donald A. Zakrowski sold 1,660 shares of the company’s stock in a transaction that occurred on Friday, February 25th. The stock was sold at an average price of $243.84, for a total transaction of $404,774.40. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 431,173 shares of company stock worth $114,549,164. Company insiders own 0.13% of the company’s stock.
Large investors have recently made changes to their positions in the business. Legacy Bridge LLC increased its position in shares of Eli Lilly and by 69.2% in the 3rd quarter. Legacy Bridge LLC now owns 110 shares of the company’s stock valued at $25,000 after purchasing an additional 45 shares during the last quarter. Wagner Wealth Management LLC grew its position in shares of Eli Lilly and by 59.4% in the 3rd quarter. Wagner Wealth Management LLC now owns 110 shares of the company’s stock valued at $28,000 after buying an additional 41 shares during the last quarter. AllSquare Wealth Management LLC purchased a new position in shares of Eli Lilly and in the 4th quarter valued at $28,000. HWG Holdings LP purchased a new position in shares of Eli Lilly and in the 4th quarter valued at $28,000. Finally, Leverty Financial Group LLC purchased a new position in shares of Eli Lilly and in the 4th quarter valued at $29,000. 82.16% of the stock is currently owned by institutional investors.
Eli Lilly and Company Profile
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.